Bayoclin
ActiveSummary
Bayoclin has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €233k and a net result of €182k. Equity is growing by ~36.9% per year across the filed fiscal years. Its solvency ranks better than 77% of 524 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.8% (low).
Checked score
Score 2025
87
/ 100
Excellent
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability100=
Solvency100=
Growth78=
Track record94
Bankruptcy probability, 12 months
0.8%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €20k at 30 days acceptable
Liquidity ample (current ratio 6.94 against 41.44 in 2024; short-term debt: 13.7% and cash: 27.2% of total assets), and 13.7% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Sector 72
lower
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
86.3%
Return on assets
67.3%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-04-2026, 95 days ahead of the deadline.
NBB · 4 filingsDeviation from the deadline
2025
95 d early
2024
49 d early
2023
47 d early
2022
55 d early
← before the deadline
after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
24-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€233k▼ 56.1%
2024 · €530k
2022: €144k
2023: €318k
2024: €530k
2022 → 2025
Total assets
€270k▼ 50.3%
2024 · €543k
2022: €197k
2023: €370k
2024: €543k
2022 → 2025
Net result
€182k▼ 14.7%
2024 · €213k
2022: €142k
2023: €174k
2024: €213k
2022 → 2025
Working capital
€219k▼ 57.2%
2024 · €513k
2022: €118k
2023: €296k
2024: €513k
2022 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line2022202320242025Trend
Equity€144k-€318k▲ 121%€530k▲ 66.6%€233k▼ 56.1%
Operating result€184k-€227k▲ 23.7%€274k▲ 20.4%€234k▼ 14.6%
Net result€142k-€174k▲ 22.8%€213k▲ 22.3%€182k▼ 14.7%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result falls in 2025; 2025 is 15% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €270k
Fixed assets
€14k ▼ 21.5%
Current assets
€256k ▼ 51.2%
Equity and liabilities €270k
Equity
€233k ▼ 56.1%
Debt
€37k ▲ 191%
Debt's share of the balance-sheet total rises from 2.3% to 13.7%. Equity is lower and debt is higher.
Key figures and ratios
EBITDA
€239k▼
2024 · €279k
Cash flow
€187k▼
2024 · €218k
Current ratio
6.94▼
2024 · 41.44
Debt to equity
0.16▲
2024 · 0.02
ROE
78.0%▲
2024 · 40.1%
ROA
67.3%▲
2024 · 39.2%
Interest coverage
3542.44▲
2024 · 3318.94
Debt ≤ 1 year
€37k▲
2024 · €13k
Income taxes
€56k▼
2024 · €66k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 41 lines
Balance sheet
Code20242025
Assets
Total assets20/58€543k€270k▼
Fixed assets21/28€17k€14k▼
Tangible fixed assets22/27€10k€6k▼
Furniture and vehicles24€10k€6k▼
Financial fixed assets28€8k€8k=
Current assets29/58€526k€256k▼
Amounts receivable within one year40/41€5k€61k▲
Other amounts receivable41€5k€61k▲
Current investments50/53€450k€100k▼
Cash at bank and in hand54/58€46k€73k▲
Deferred charges and accrued income490/1€24k€22k▼
Equity and liabilities
Total equity and liabilities10/49€543k€270k▼
Equity10/15€530k€233k▼
Contributions10/11€3k€3k=
Reserves13€528k€230k▼
Distributable reserves133€528k€230k▼
Amounts payable17/49€13k€37k▲
Amounts payable within one year42/48€13k€37k▲
Trade debts44€2k€586▼
Suppliers440/4€2k€586▼
Taxes, remuneration and social security45€9k€9k=
Taxes450/3€9k€9k=
Other amounts payable47/48€859€27k▲
Income statement
Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€5k€5k▲
Other operating charges640/8€892€1k▲
Gross operating margin9900€280k€240k▼
Operating profit (loss)9901€274k€234k▼
Financial income75/76B€6k€4k▼
Recurring financial income75€6k€4k▼
Financial charges65/66B€84€68▼
Recurring financial charges65€84€68▼
Profit (loss) for the period before taxes9903€279k€237k▼
Income taxes67/77€66k€56k▼
Profit (loss) for the period9904€213k€182k▼
Profit (loss) for the period to be appropriated9905€213k€182k▼
Appropriation of the result
Profit (loss) to be appropriated9906€213k€182k▼
Transfer from equity791/2-€479k
Transfer to equity691/2€212k€182k▼
To other reserves6921€212k€182k▼
Profit to be distributed694/7€859€479k▲
Return on contributions (dividend)694€859€479k▲
The notes to these accounts (6 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
27-04
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
12-06
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
31-12
Financial
Highest result since 2022net €213k ▲22.3%
Operating result €274k, net result €213k, both a record.
31-12
Financial
Liquidity times 6current ratio 41.44
Current ratio from 6.75 to 41.44; short-term debt falls from €51k to €13k.
31-12
Financial
Equity above €500kEq €530k ▲66.6%
3 profitable years in a row build equity to €530k.
14-06
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
31-12
Financial
Liquidity doublescurrent ratio 6.75
Current ratio from 3.22 to 6.75; short-term debt falls from €53k to €51k.
31-12
Financial
Equity above €200kEq €318k ▲121%
2 profitable years in a row build equity to €318k.
06-06
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Nivelles · 1 establishment unit since 2021
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Avenue de Vaillampont 131402 NivellesGround area
4,947 m²
Building footprint
150 m²
Volume, LiDAR
722 m³
Parcel 25099D0053/00C000, Wallonia · tallest building 6.3 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
Bayoclin
since 20212.324.524.034
1 parcel
Wallonia
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 25099D0053/00C000 | Wallonia | 4,947 m² | 1 · 150 m² | 6.3 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
MENTANA DX
BE 0786.290.908
Evergem · Eq €228,548
ClinInnov
BE 0805.203.928
Ciney · Eq €237,541
Global Mobile Lab
BE 0763.504.816
Saint-Hubert · Eq €237,750
CBaBC
BE 0783.308.058
Destelbergen · Eq €227,814
NorthboundBio
BE 1008.524.836
Leuven · Eq €226,519
Of 761 companies in sector 72101 we hold annual accounts for 481. 327 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded27-10-2021
Fiscal year end31-12
Activities, NACEBEL 2025
72101Research and development on biotechnology
Sources
Crossroads Bank for EnterprisesNational Bank · 4 filingsAddress and cadastre registers
Scores and ratios are computed by Checked and are not a credit decision.